Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Saccharin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 7/20 | 0.92 |
| ▸ | CA9 | Q16790 | 7/20 | 0.92 |
| ▸ | CA2 | P00918 | 5/20 | 0.92 |
| ▸ | CA1 | P00915 | 4/20 | 0.92 |
| ▸ | CA7 | P43166 | 3/20 | 0.92 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.92 |
| ▸ | CA4 | P22748 | 2/20 | 0.92 |
| ▸ | USP2 | O75604 | 1/20 | 0.92 |
| ▸ | LMNA | P02545 | 1/20 | 0.92 |
| ▸ | BCHE | P06276 | 1/20 | 0.92 |
| ▸ | CA6 | P23280 | 1/20 | 0.92 |
| ▸ | CA5A | P35218 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.92 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.92 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | GRK5 | P34947 | 2/20 | 0.52 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saccharin SCHEMBL27530252 | 1.00 | CA12 (0.92) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL8728937 | 0.98 | CA12 (0.96) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL28835159 | 0.98 | CA12 (0.96) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL1286764 | 0.98 | CA12 (0.96) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL29453372 | 0.98 | CA12 (0.96) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL17888788 | 0.98 | CA12 (0.96) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL28876486 | 0.98 | CA12 (0.96) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL435836 | 0.98 | CA12 (0.96) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL29646267 | 0.96 | CA12 (0.92) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL485939 | 0.96 | CA12 (0.92) | CA12CA9CA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1169062-B1 | HEAT STABLE COATED COLLOIDAL IRON OXIDES | AMAG PHARMACEUTICALS INC (US) | 2009-10-21 | — | — | EP | claimed |
| EP-1522318-A2 | Heat stable coated colloidal iron oxides | ADVANCED MAGNETICS INCORPORATED (US) | 2005-04-13 | — | — | EP | claimed |
| US-20030225033-A1 | Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof | COVIS PHARMA GMBH (CH) | 2003-12-04 | — | — | US | claimed |
| US-6599498-B1 | Enhanced magnetic resonance imaging agent and a hematinic agent; carboxyalkylated reduced polysaccharides coated ultrasmall superparamagnetic iron oxides; carboxymethyl reduced dextran as a plasma extender | ADVANCED MAGNETICS, INC. | 2003-07-29 | — | — | US | claimed |
| JP-2002541218-A | — | — | 2002-12-03 | — | — | JP | claimed |
| EP-1169062-A2 | HEAT STABLE COATED COLLOIDAL IRON OXIDES | ADVANCED MAGNETICS INCORPORATED (US) | 2002-01-09 | — | — | EP | claimed |
| WO-2000061191-A9 | HEAT STABLE COATED COLLOIDAL IRON OXIDES | ADVANCED MAGNETICS INC (US) | 2001-06-21 | — | — | WO | claimed |
| WO-2000061191-A2 | HEAT STABLE COATED COLLOIDAL IRON OXIDES | ADVANCED MAGNETICS, INC. (US) | 2000-10-19 | — | — | WO | claimed |
| US-20230008240-A1 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON | AMERICAN REGENT, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11364260-B2 | Methods and compositions for administration of iron | AMERICAN REGENT, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-11344568-B2 | Methods and compositions for administration of iron | AMERICAN REGENT, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200215097-A1 | METHODS AND COMPOSITIONS FOR ADMINSTRATION OF IRON | AMERICAN REGENT, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20200215096-A1 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON | AMERICAN REGENT, INC. | 2020-07-09 | — | — | US | disclosed |
| US-10478450-B2 | Methods and compositions for administration of iron | LUITPOLD PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20030225033-A1 | Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof | COVIS PHARMA GMBH (CH) | 2003-12-04 | — | — | US | disclosed |
| US-6599498-B1 | Enhanced magnetic resonance imaging agent and a hematinic agent; carboxyalkylated reduced polysaccharides coated ultrasmall superparamagnetic iron oxides; carboxymethyl reduced dextran as a plasma extender | ADVANCED MAGNETICS, INC. | 2003-07-29 | — | — | US | disclosed |
| EP-1169062-A2 | HEAT STABLE COATED COLLOIDAL IRON OXIDES | ADVANCED MAGNETICS INCORPORATED (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061191-A9 | HEAT STABLE COATED COLLOIDAL IRON OXIDES | ADVANCED MAGNETICS INC (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000061191-A2 | HEAT STABLE COATED COLLOIDAL IRON OXIDES | ADVANCED MAGNETICS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| US-5204457-A | Used in nuclear magnetic resonance imaging; forming carboxy-alkylether of a polysaccharide and complexing with magnetic metal oxide | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1993-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225033-A1 | Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof | TFRC, FUCA2, FTH1 | ACVR1 4216/4885CA12 105/4885CA9 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.